The 38 references in paper I. Romanov S., A. Mudunov M., P. Isaev A., Yu. Bychkov M., M. Dolgushin B., A. Odzharova A., L. Romanova F., И. Романов С., А. Мудунов М., П. Исаев А., Ю. Бычков М., М. Долгушин Б., А. Оджарова А., Л. Романова Ф. (2017) “ЛЕНВАТИНИБ В ЛЕЧЕНИИ РАДИОЙОДРЕФРАКТЕРНОГО ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ // LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA” / spz:neicon:ogsh:y:2017:i:2:p:45-52

1
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИРЦ» Минздрава России,
(check this in PDF content)
2
17. 250 с. 2. American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society. Available at http://www.cancer.org/acs/ groups/content/@research/documents/ webcontent/acspc-042151. Accessed August 13, 2014.
(check this in PDF content)
3
Furuya-Kanamori L., Bell K.J.L., Clark J. et al. Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis. Journal of Clinical Oncology 2016;34(30):3672–9.
(check this in PDF content)
4
Румянцев П.О., Ильин А.А., Румянцева У.В. и др. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАРМедиа, 2009. [Rumyantsev P.O., Ilyin A. A., Rumjantseva U.V., etc. Cancer of the thyroid cancer. Modern approaches to diagnosis and treatment. Moscow: GEOTARMedia, 2009. (In Russia)].
(check this in PDF content)
5
O’Neill C.J., Oucharek J., Learoud D. et al. Standard and emerging therapies for metastatic differentiated thyroid cancer. The Oncologist 2010;15(2):146–56.
(check this in PDF content)
6
Sherman S.I. Thyroid carcinoma. Lancet 2003;361:501–11.
(check this in PDF content)
7
Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:313–9.
(check this in PDF content)
8
Adam M.A., Thomas S., Hyslop T. et al. Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. Journal of Clinical Oncology 2016;34(36):4415–20.
(check this in PDF content)
9
Hoie J., Stenwig A.E., Kullmann G. et al. Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer 1988;61:1–6.
(check this in PDF content)
10
Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.
(check this in PDF content)
11
Pittas A.G., Adler M., Fazzari M. et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261–8.
(check this in PDF content)
12
Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.
(check this in PDF content)
13
Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:1626–31.
(check this in PDF content)
14
Hodak S.P., Carty S.E. Radioiodineresistant differentiated thyroid cancer: hope for the future. Oncology 2009;9:775–6.
(check this in PDF content)
15
Brose M., Nutting C.M., Sherman S.I. et al. Rationale and design of decision: a double-blind, randomized, placebo- controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349–70.
(check this in PDF content)
16
Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;3:4–9.
(check this in PDF content)
17
Резолюция Экспертного совета по вопросам таргетной терапии дифференцированного рака щитовидной железы, резистентного к терапии радиоактивным йодом. Опухоли головы и шеи 2014;3:10–1.
(check this in PDF content)
18
Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8.
(check this in PDF content)
19
Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1–133.
(check this in PDF content)
20
Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155–60.
(check this in PDF content)
21
Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:405–7.
(check this in PDF content)
22
Nikiforova M.N., Nikiforov Y.E. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83–95.
(check this in PDF content)
23
Riesco-Eizaguirre G., Gutierrez-Martinez P., Garcia-Cabezas M.A. et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13:257–69.
(check this in PDF content)
24
Durante C., Puxeddu E., Ferretti E. et al. RAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840–3.
(check this in PDF content)
25
Romei C., Ciampi R., Faviana P. et al. BRAF V600E mutation, but not RET/ PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008;15:511–20.
(check this in PDF content)
26
Liu Z., Hou P., Ji M. et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/ Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106–16.
(check this in PDF content)
27
Santarpia L., El-Naggar A.K., Cote G.J. et al. Phosphatidylinositol 3-kinase/Akt and Ras/Raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278–84.
(check this in PDF content)
28
Liu R., Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016;23(3):R143–R155.
(check this in PDF content)
29
Liu X., Bishop J., Shan Y. et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20(4):603–10.
(check this in PDF content)
30
Horn S., Figl A., Rachakonda P.S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339(6122):959–61.
(check this in PDF content)
31
Huang F.W., Hodis E., Xu M.J. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339(6122):957–9.
(check this in PDF content)
32
Liu R., Bishop J., Zhu G. et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. JAMA Oncology Published online September 1, 2016.
(check this in PDF content)
33
Castellone M.D., Carlomagno F., Salvatore G. et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008;22:1023–38.
(check this in PDF content)
34
Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–30.
(check this in PDF content)
35
Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65.
(check this in PDF content)
36
Grande E., Diez J.J., Zafon C. et al. Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res 2012;2012:847108.
(check this in PDF content)
37
Stjepanovic N., Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014;8:129–39.
(check this in PDF content)
38
Gianoukakis A.G. et al. Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): Updated results from SELECT.
(check this in PDF content)